801 related articles for article (PubMed ID: 12404782)
1. [New anxiolytic drugs: methodological issues].
Ginestet D; Corruble E
Encephale; 1993; 19(6):627-37. PubMed ID: 12404782
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of generalized anxiety: new pharmacologic approaches].
Boulenger JP
Encephale; 1995; 21(6):459-66. PubMed ID: 8674471
[TBL] [Abstract][Full Text] [Related]
3. Clinical methodology for testing of anxiolytic drugs.
Bourin M
Therapie; 2000; 55(1):147-53. PubMed ID: 10860018
[TBL] [Abstract][Full Text] [Related]
4. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of 6 different methods for lorazepam withdrawal. A controlled study, hydroxyzine versus placebo].
Lemoine P; Touchon J; Billardon M
Encephale; 1997; 23(4):290-9. PubMed ID: 9417395
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
Small GW; Bystritsky A
J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
[TBL] [Abstract][Full Text] [Related]
7. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
Pollack MH; Worthington JJ; Manfro GG; Otto MW; Zucker BG
J Clin Psychiatry; 1997; 58 Suppl 11():19-23. PubMed ID: 9363044
[TBL] [Abstract][Full Text] [Related]
8. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
Mercier-Guyon C; Chabannes JP; Saviuc P
Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
[TBL] [Abstract][Full Text] [Related]
9. [Neuropsychological evaluation and psychopathology of multiple sclerosis].
Defer G
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1128-34. PubMed ID: 11787345
[TBL] [Abstract][Full Text] [Related]
10. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
Naukkarinen H; Raassina R; Penttinen J; Ahokas A; Jokinen R; Koponen H; Lepola U; Kanerva H; Lehtonen L; Pohjalainen T; Partanen A; Mäki-Ikola O; Rouru J;
Eur Neuropsychopharmacol; 2005 Dec; 15(6):617-23. PubMed ID: 15949921
[TBL] [Abstract][Full Text] [Related]
11. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
12. Safety of ipsapirone treatment compared with lorazepam: discontinuation effects.
Busto UE; Naranjo CA; Bremner KE; Peachey JE; Bologa M
J Psychiatry Neurosci; 1998 Jan; 23(1):35-44. PubMed ID: 9505058
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice.
Nguyen N; Fakra E; Pradel V; Jouve E; Alquier C; Le Guern ME; Micallef J; Blin O
Hum Psychopharmacol; 2006 Apr; 21(3):139-49. PubMed ID: 16625522
[TBL] [Abstract][Full Text] [Related]
14. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
[TBL] [Abstract][Full Text] [Related]
15. New anxiolytics in development.
Mosconi M; Chiamulera C; Recchia G
Int J Clin Pharmacol Res; 1993; 13(6):331-44. PubMed ID: 7916335
[TBL] [Abstract][Full Text] [Related]
16. On the therapeutic action of alpidem in anxiety disorders: an overview of the European data.
Morselli PL
Pharmacopsychiatry; 1990 May; 23 Suppl 3():129-34. PubMed ID: 1974073
[TBL] [Abstract][Full Text] [Related]
17. [Clinical evaluation of new anxiolytic drugs (author's transl)].
Boulenger JP
Nouv Presse Med; 1982 May; 11(22):1687-94. PubMed ID: 6124934
[TBL] [Abstract][Full Text] [Related]
18. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
19. Long-term anxiolytic therapy: the issue of drug withdrawal.
Lader M
J Clin Psychiatry; 1987 Dec; 48 Suppl():12-6. PubMed ID: 2891684
[TBL] [Abstract][Full Text] [Related]
20. Nonbenzodiazepine anxiolytics: clinical usefulness.
Rickels K
J Clin Psychiatry; 1983 Nov; 44(11 Pt 2):38-44. PubMed ID: 6139368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
